[ad_1]
The University of Oxford and AstraZeneca have begun work on a version of their omicron-targeted coronavirus vaccine, the Financial Times (FT) reported today.
The head of the research team in Oxford, Sandy Douglas told FT that the first steps have been taken in the production of a modified vaccine, in case it is necessary, together with their partners, the company AstraZeneca.
“Adenovirus-based vaccines, such as those made by Oxford / AstraZeneca, can in principle be used to respond to any new variant faster than previously thought,” Douglas added. The effectiveness of omicron-type coronavirus vaccines has dropped significantly, the director of European Emergency Medicine (EMA) Emer Cook said yesterday.
“The data that has arrived is not conclusive, there are very few of them, but it is clear that there is a decrease in efficiency over the omicron variant,” Cook told the Financial Times, reports Reuters.
According to experts, a full vaccination cycle can protect against severe forms of the disease, while, according to the newspaper, preliminary evidence shows that a boosting dose of mRNA vaccine may partially increase antibody levels. According to the EMA, the decision on whether a special vaccine against the omicron variant is needed will be made when sufficient scientific evidence is gathered that “existing vaccines do not work”.
top channel
[ad_2]
Source link
